Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin

European Journal of Radiology

Volumn 70, Issue 1, 2009, Pages 17-24

  Kim, Seong Jang ^a   Lee, Tae Hong ^a   Kim, In Ju ^a   Kim, Yong Ki ^a  

^a Pusan National University Hospital   (South Korea)

Author keywords

F 18 FDG; Iodine 123; Iodine 131; PET CT; Thyroglobulin; Thyroid cancer

Indexed keywords

F-18 FDG; IODINE-123; IODINE-131; PET/CT; THYROGLOBULIN; THYROID CANCER;

BODY FLUIDS; DOSIMETRY; GLYCOPROTEINS; INDUSTRIAL CHEMICALS; PATHOLOGY;

IODINE;

FLUORODEOXYGLUCOSE F 18; IODINE 123; THYROGLOBULIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER;

ADULT; AGED; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 63649144933     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2007.12.004     Document Type: Article

References (37)

1. 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol Metab 53 (1981) 1199-1206
2. Ozata M., Suzuki S., Miyamoto T., et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79 (1994) 98-105
3. Filesi M., Signore A., Ventroni G., Melacrinis F., and Ronga G. Role of initial iodine-131 whole body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 39 (1998) 1542-1546
4. Sherman S.I. Thyroid carcinoma. Lancet 361 (2003) 501-511
5. 131I whole-body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid 14 (2004) 301-306
6. Baudin E., Do Cao D., Cailleux A.F., Leboulleux S., Travagli J.P., and Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endrinol Metab 88 (2003) 1107-1111
7. Wang W., Macapinlac H., Larson S.M., et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scan and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84 (1999) 2291-2302
8. Schlumberger M. Papillary and follicular carcinoma. N Engl J Med 338 (1998) 297-306
9. Strauss L.G., and Conti P.S. The applications of PET in clinical oncology. J Nucl Med 32 (1991) 623-648
10. Altenvoerde G., Lerch H., Kuwert T., Matheja P., Schäfers M., and Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scan. Lagenbeck's Arch Surg 383 (1998) 160-163
11. 131I whole body scan. J Nucl Med 40 (1999) 986-992
12. 131I-negative papillary thyroid carcinoma. J Nucl Med 41 (2000) 1010-1015
13. 131I scan. J Nucl Med 42 (2001) 71-76
14. 131I scanning results after therapy. J Nucl Med 42 (2001) 1464-1469
15. 18F fluorodeoxyglucose positron emission tomography in patients with radio-iodine negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234 (2001) 804-811
16. Coleman R.E., Delbeke D., Guiberteau M.J., et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society if Computed Body Tomography and Magnetic Resonance. J Nucl Med 46 (2005) 1225-1239
17. Galloway R.J., and Smallridge R.C. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 25 (1996) 93-113
18. 131I for whole body imaging in thyroid cancer. J Nucl Med 43 (2002) 632-634
19. Thyroid gland. In: Fleming I.D., Cooper J.S., Henson D.E., et al. (Eds). American Joint Committee on Cancer: AJCC cancer staging manual. 5th ed. (1997), Lippincott-Raven, Philadelphia, PA 59-61
20. Hoh C.K., Schiepers C., Seltzer M.A., et al. PET in oncology: will it replace the other modalities?. Semin Nucl Med 27 (1997) 94-106
21. Hundahl S.A., Fleming I.D., Fremgen A.M., et al. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US 1985-1995. Cancer 83 (1998) 2638-2648
22. Mazzaferri E.L., and Kloos R.T. Carcinoma of follicular epithelium: radioiodine and other treatments and outcomes. In: Braverman L.E., and Utiger R.D. (Eds). The thyroid. The fundamental and clinical test (Werner and Ingbar). 9th ed. (2005), Lippincott Williams & Wilkins, Philadelphia 934-966
23. Pacini F., Lippi F., Formica N., et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28 (1987) 1888-1891
24. Grünwald F., Schomburg A., Bender H., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imag 23 (1996) 312-319
25. Feine U., Lietzenmayer R., Hanke J., Held J., Wohrle H., and Muller-Schauenburg W. Fluorine-18-FDG and iodine-131 uptake in thyroid cancer. J Nucl Med 37 (1996) 1468-1472
26. Ong S.C., Ng D.C.E., and Sundram F.X. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scan. Singapore Med J 46 (2005) 297-301
27. Nahas Z., Goldenberg D., Fakhry C., et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115 (2005) 237-243
28. Phan T.T.H., van Tol K.M., Links T.P., et al. Diagnostic I-131 scintigraphy in patients with differentiated thyroid cancer: no additional value of higher scan dose. Ann Nucl Med 18 (2004) 614-646
29. 131I therapy for elevated thyroglobulin levels. Thyroid 7 (1997) 273-276
30. Pineda J.D., Lee T., Ain K., et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80 (1995) 1488-1492
31. Moog F., Linke R., Manthey N., et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41 (2000) 1989-1995
32. 18F fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 29 (2002) 641-647
33. 131I ablative therapy. J Nucl Med 40 (1999) 1434-1440
34. 131I in the detection of differentiated thyroid cancer metastases. Nucl Med Commun 21 (2000) 917-923
35. Brandt-Mainz K., Muller S.P., Sonnenschein W., and Bockisch A. Technetium-99m furifosmin in the follow-up of differentiated thyroid carcinoma. J Nucl Med (1998) 1536-1541
36. 131I whole body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J Nucl Med 41 (2000) 631-635
37. 99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation. Thyroid 8 (1998) 1091-1100